Santhera Pharmaceuticals

News Santhera Pharmaceuticals

• Santhera Joins EU-funded EndoStem Consortium in Preparation for Clinical Study with Omigapil in Congenital Muscular Dystrophies

  Santhera Pharmaceuticals announced its participation in the EndoStem Consortium, a pan-European partnership of 15 academic and industry teams. EndoStem is co-funded by the European Union and seeks to accelerate the development of effective therapies for muscular dystrophies. In collaboration with th more

• Santhera Obtains US Patent for Use of Catena in the Treatment of Muscular Dystrophies

  Santhera Pharmaceuticals announced that the United States Patent and Trademark Office granted patent protection for the use of idebenone (brand name Catena®) in the treatment of Duchenne Muscular Dystrophy and other muscular dystrophies. The patent in the United States is supplemented by a similar p more

• Santhera Presents Data from 2-Year Open-Label Intervention Study with Catena in Duchenne Muscular Dystrophy

  Santhera Pharmaceuticals announced that it will present first analyses of the 2-year open-label study (DELPHI-E) evaluating Catena® for the treatment of Duchenne Muscular Dystrophy. The findings indicate that Catena® can slow the decline in respiratory function associated with patients as they age. more

Websites Santhera Pharmaceuticals